Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Bhutani M et al. Lancet Haematol. 2017 Sep;4(9):e443-e451. doi: 10.1016/S2352-3026(17)30143-6.

Detection of Circulating Plasma Cells in Multiple Myeloma.
Alix-Panabières C et al. Clin Chem. 2017 Sep 18. pii: clinchem.2017.275446. doi: 10.1373/clinchem.2017.275446. [Epub ahead of print].

Quantitative analysis of 18F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma.
Sachpekidis C et al. Am J Nucl Med Mol Imaging. 2017 Sep 1;7(4):148-156. eCollection 2017.

Prospective Identification of Oligoclonal/Abnormal Band of the Same Immunoglobulin Type as the Malignant Clone by Differential Location of M-Spike and Oligoclonal Band.
Vyas SG et al. J Clin Med Res. 2017 Oct;9(10):826-830. doi: 10.14740/jocmr3109w. Epub 2017 Sep 1.

MDR1 polymorphisms affect the outcome of Chinese multiple myelomapatients.
Xiao Z et al. Biomed Pharmacother. 2017 Sep 6;95:743-748. doi: 10.1016/j.biopha.2017.08.142. [Epub ahead of print].

The serum heavy/light chain immunoassay: a valuable tool for sensitive paraprotein assessment, risk and disease monitoring in monoclonal gammopathies.
Greil C et al. Eur J Haematol. 2017 Sep 8. doi: 10.1111/ejh.12958. [Epub ahead of print].

Methionine PET Might Be Reliable for the Detection of Low M-Protein-Producing Myelomas.
Imataki O et al. Clin Nucl Med. 2017 Sep 1. doi: 10.1097/RLU.0000000000001821. [Epub ahead of print].

High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma.
Wang L et al. Ann Hematol. 2017 Sep 5. doi: 10.1007/s00277-017-3125-4. [Epub ahead of print].

Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry.
Alaterre E et al. Cytometry B Clin Cytom. 2017 Sep 2. doi: 10.1002/cyto.b.21590. [Epub ahead of print].

IMiD-induced gene expression profiling predicts multiple myelomaprognosis.
Sebastian S. Lancet Haematol. 2017 Sep;4(9):e406-e407. doi: 10.1016/S2352-3026(17)30153-9.

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma.
Binder M et al. Blood Cancer J. 2017 Sep 1;7(9):e600. doi: 10.1038/bcj.2017.83.

Failure to achieve early disease response is associated with inferior survival in patients with newly diagnosed multiple myeloma.
Chee A et al. Br J Haematol. 2017 Aug 31. doi: 10.1111/bjh.14871. [Epub ahead of print].

The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma.
Roh J et al. Oncotarget. 2017 Jul 22;8(35):58122-58132. doi: 10.18632/oncotarget.19468. eCollection 2017 Aug 29.

High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma.
Miller A et al. Blood Cancer J. 2017 Sep 22;7(9):e612. doi: 10.1038/bcj.2017.94.